GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Asset Turnover

INMB (INmune Bio) Asset Turnover : 0.00 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. INmune Bio's Revenue for the three months ended in Mar. 2025 was $0.05 Mil. INmune Bio's Total Assets for the quarter that ended in Mar. 2025 was $38.68 Mil. Therefore, INmune Bio's Asset Turnover for the quarter that ended in Mar. 2025 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. INmune Bio's annualized ROE % for the quarter that ended in Mar. 2025 was -126.13%. It is also linked to ROA % through Du Pont Formula. INmune Bio's annualized ROA % for the quarter that ended in Mar. 2025 was -100.71%.


INmune Bio Asset Turnover Historical Data

The historical data trend for INmune Bio's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Asset Turnover Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only - - - - -

INmune Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of INmune Bio's Asset Turnover

For the Biotechnology subindustry, INmune Bio's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Asset Turnover distribution charts can be found below:

* The bar in red indicates where INmune Bio's Asset Turnover falls into.


;
;

INmune Bio Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

INmune Bio's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.014/( (57.001+39.562)/ 2 )
=0.014/48.2815
=0.00

INmune Bio's Asset Turnover for the quarter that ended in Mar. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=0.05/( (39.562+37.801)/ 2 )
=0.05/38.6815
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


INmune Bio  (NAS:INMB) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

INmune Bio's annulized ROE % for the quarter that ended in Mar. 2025 is

ROE %**(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-38.956/30.885
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-38.956 / 0.2)*(0.2 / 38.6815)*(38.6815/ 30.885)
=Net Margin %*Asset Turnover*Equity Multiplier
=-19478 %*0.0052*1.2524
=ROA %*Equity Multiplier
=-100.71 %*1.2524
=-126.13 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

INmune Bio's annulized ROA % for the quarter that ended in Mar. 2025 is

ROA %(Q: Mar. 2025 )
=Net Income/Total Assets
=-38.956/38.6815
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-38.956 / 0.2)*(0.2 / 38.6815)
=Net Margin %*Asset Turnover
=-19478 %*0.0052
=-100.71 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


INmune Bio Asset Turnover Related Terms

Thank you for viewing the detailed overview of INmune Bio's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Executives
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016